Rubella – Diagnostics – Overview of Information and Clinical Research

Rubella, also known as German measles or three-day measles, is a viral infection that causes a distinctive rash and other mild symptoms in most people, but its diagnosis becomes critically important for pregnant women and public health monitoring, as the infection can lead to devastating consequences for unborn babies.

Introduction: Who Should Undergo Diagnostics

If you notice a rash that starts on your face and spreads to your neck and body, accompanied by a mild fever, you may wonder whether it’s rubella. While many viral illnesses cause similar rashes, getting the right diagnosis matters greatly. This is especially true for certain groups of people who face higher risks from rubella infection.^[1]

Pregnant women should seek diagnostic testing immediately if they develop a rash or believe they have been exposed to someone with rubella. The virus poses the greatest danger during the first trimester of pregnancy, when infection can cause miscarriage, stillbirth, or serious birth defects known as congenital rubella syndrome, which is a condition that affects multiple organs in the developing baby. Up to 90 percent of babies whose mothers contract rubella early in pregnancy will suffer serious complications.^[9]

Anyone who has not been vaccinated against rubella or doesn’t know their vaccination status should consider diagnostic testing if symptoms appear. Healthcare workers and childcare staff need to know their immune status because they work closely with vulnerable populations. If you have been near someone diagnosed with rubella, especially if you’re pregnant or work with pregnant individuals, you should contact a healthcare provider even if you feel fine.^[2]

It’s worth noting that up to half of all people infected with rubella never develop symptoms, yet they can still spread the virus to others. This makes diagnosis particularly important from a public health perspective. You can be contagious for about a week before and a week after the rash appears, which means you might unknowingly expose others during this time.^[12]

⚠️ Important

If you suspect rubella, call your healthcare provider before visiting in person. The disease spreads easily through coughs and sneezes, so alerting the office ahead of time allows them to take precautions to protect other patients, particularly pregnant women. Some providers may suggest a phone consultation first to determine if testing is needed.

Diagnostic Methods for Identifying Rubella

Because rubella looks similar to many other viral rashes, healthcare professionals cannot confirm the diagnosis just by looking at your skin. Visual examination alone is unreliable for identifying rubella, which is why laboratory testing becomes essential. The rash from rubella can resemble measles, roseola, and other common viral infections, making it nearly impossible to distinguish based on appearance alone.^[11]

Blood Tests for Rubella Antibodies

The most common way doctors confirm rubella is through blood tests that look for specific antibodies, which are proteins your body produces to fight the rubella virus. When you get infected, your immune system creates two main types of antibodies at different times. Understanding these antibodies helps doctors determine whether you have an active infection or were exposed to rubella in the past.^[6]

IgM antibodies appear first when you have an active or recent rubella infection. These antibodies typically show up in your blood within a few days after the rash appears. If a blood test finds IgM antibodies, it suggests you currently have rubella or were recently infected. However, IgM antibodies don’t last forever—they gradually disappear over several weeks to months after the infection clears.^[2]

IgG antibodies develop later and remain in your blood for life. If testing shows IgG antibodies but no IgM antibodies, this usually means you had rubella at some point in the past, either through natural infection or vaccination. These antibodies indicate you are immune to rubella and protected from future infections. This distinction matters greatly for pregnant women, as the presence of IgG antibodies without IgM suggests protection rather than active infection.^[12]

Virus Culture and Detection

In addition to antibody tests, healthcare providers can sometimes detect the rubella virus itself in body fluids. A virus culture involves collecting samples from your throat, nose, or urine and testing them for the presence of rubella virus. This method works best when done during the early stages of infection, particularly when the rash first appears. However, virus cultures take longer to process than blood tests and require specialized laboratory facilities.^[11]

More advanced laboratories can use molecular techniques to detect rubella RNA, which is the genetic material of the virus. These RNA detection methods can identify very small amounts of virus in clinical samples. While these tests are highly accurate, they are typically used more for public health surveillance and outbreak investigations than for routine diagnosis of individual patients.^[4]

Timing and Accuracy of Testing

The timing of diagnostic testing affects accuracy. If you get tested too early after exposure, your body may not have produced enough antibodies yet for the test to detect. Symptoms of rubella typically appear between 14 and 21 days after you’ve been near someone with the infection. This time period, called the incubation period, is when the virus multiplies in your body before symptoms emerge.^[1]

Healthcare providers consider your vaccination history when interpreting test results. If you received both doses of the MMR vaccine (which protects against measles, mumps, and rubella), you should have IgG antibodies in your blood. Finding these antibodies in a vaccinated person doesn’t mean you have rubella—it means the vaccine worked properly. This is why knowing your vaccination status helps doctors understand what test results mean for your specific situation.^[2]

Diagnostics for Clinical Trial Qualification

Clinical trials studying rubella or testing interventions related to the disease typically require specific diagnostic criteria for patient enrollment. While rubella clinical trials are relatively uncommon in countries where vaccination has eliminated the disease, they may occur in regions where rubella remains prevalent or when researchers study congenital rubella syndrome.^[13]

For trials investigating rubella itself, confirmed diagnosis through laboratory testing is essential. Researchers cannot rely on clinical symptoms alone because of how similar rubella appears to other viral infections. Most clinical trial protocols require either positive IgM antibody results or confirmed virus detection through culture or RNA testing. These strict diagnostic requirements ensure that study participants actually have rubella rather than another condition with similar symptoms.^[4]

Studies focusing on congenital rubella syndrome require additional diagnostic evaluations of newborns. Infants born to mothers who had rubella during pregnancy undergo comprehensive testing, including blood tests to detect rubella-specific antibodies that the baby’s own immune system produced (rather than antibodies passed from the mother). Healthcare providers also collect samples from the baby’s throat and urine to test for ongoing virus shedding. Babies with congenital rubella syndrome can continue releasing virus for a year or longer, which has important implications for clinical trial design and safety protocols.^[17]

Clinical trials involving pregnant women and rubella exposure use serology testing to determine immunity status before enrollment. Women participating in such studies need baseline testing to establish whether they have protective IgG antibodies from previous infection or vaccination. If a pregnant woman lacks these antibodies and gets exposed to rubella during the study, rapid diagnostic testing helps researchers track outcomes and intervene appropriately. Some research protocols may test for both IgM and IgG antibodies at specific intervals throughout pregnancy to monitor for new infections.^[12]

Prevention trials testing rubella vaccines require pre-vaccination and post-vaccination antibody testing to measure immune response. Researchers check IgG antibody levels before giving the vaccine to identify participants who already have immunity. After vaccination, they measure antibody levels again to determine how well the vaccine worked. These studies help establish the effectiveness of vaccination programs and guide public health recommendations about dosing schedules.^[13]

⚠️ Important

Women planning to participate in clinical trials should know their rubella immunity status before becoming pregnant. Healthcare providers typically test women of childbearing age for rubella antibodies as part of preconception care. If testing shows no immunity, vaccination should occur at least one month before pregnancy. Pregnant women should never receive the rubella vaccine, as it contains live virus, though accidental vaccination during early pregnancy has not been proven to cause problems.

Prognosis and Survival Rate

Prognosis

The outlook for people who contract rubella outside of pregnancy is generally excellent. Most children and adults recover completely within about three days to one week without any long-term complications. The infection typically causes only mild symptoms such as rash, low fever, and swollen glands. Some adults, particularly women, may experience joint pain that can persist for a few weeks or even a month after the rash disappears, but this symptom rarely causes permanent problems. Serious complications such as brain inflammation or severe bleeding problems occur rarely in people who are not pregnant.^[8]

The prognosis changes dramatically for pregnant women and their unborn babies. When a woman contracts rubella during the first trimester of pregnancy, up to 90 percent of fetuses will develop serious complications. The earlier in pregnancy the infection occurs, the more severe the potential damage. Infection during the first eight to ten weeks carries the highest risk of multiple birth defects. The risk decreases as pregnancy progresses, and defects become rare after 20 weeks of pregnancy. However, any rubella infection during pregnancy warrants close medical monitoring and specialized obstetric care.^[9]

Babies born with congenital rubella syndrome face varied prognoses depending on which organs are affected and the severity of their conditions. Some infants may have only one problem, such as hearing loss, while others suffer from multiple complications affecting the heart, eyes, brain, and other organs. Children with congenital rubella syndrome often require lifelong specialized care and support. Some health problems associated with the syndrome, such as diabetes, may not appear until later in childhood rather than at birth. Early intervention programs can help maximize development and quality of life for affected children.^[7]

Survival rate

Rubella infection in children and non-pregnant adults has a survival rate approaching 100 percent. Deaths from rubella in healthy individuals are extremely rare. Even when complications such as brain inflammation occur, most patients survive with appropriate medical care. The disease itself is mild enough that many infected people never realize they had rubella.^[8]

For unborn babies exposed to rubella, survival rates depend heavily on when during pregnancy the mother’s infection occurred. First trimester infections carry significant risks of miscarriage and fetal death. Up to 85 percent of infants infected with rubella during the first trimester will either die before birth or be born with serious birth defects. Babies who survive to birth with congenital rubella syndrome generally have a good survival rate into childhood, though they face ongoing health challenges. The specific complications they experience, particularly severe heart defects, influence long-term survival outcomes.^[5]

#1 Clinical Trials Search in Europe